C onnective tissue growth factor (CTGF), 1 a member of CCN family (CTGF, CYR61, and NOV), 1 which is also named insulin-like growth factor binding protein 8 (IGFBP-8), belongs to the "immediate-early response genes" that are expressed after induction by serum, growth factors, and cytokines. 2 CTGF has a low insulin-like growth factor (IGF) activity, but has also IGF-independent actions by acting as a chemotactic and mitogenic factor for connective tissue cells. 3, 4 CTGF is overexpressed at high levels during atherosclerosis and fibrotic disorders such as scleroderma. 5, 6 However, CTGF at low levels supports wound repair and plays a role in embryogenesis and uterine function. [7] [8] [9] These beneficial processes are most likely mediated by the mitogenic, chemotactic, and matrix-inducing effects of CTGF, such as the ability to stimulate the expression of fibronectin, type I collagen, and ␣ 5 integrin. 10 CTGF expression is upregulated by dexamethasone 11 and by transforming growth factor-␤1 (TGF-␤) by means of a regulatory element located within the promoter sequence. 12 Moreover, levels of TGF-␤ and CTGF seem to correlate during wound repair. 7 On the other hand, CTGF expression is inhibited by tumor necrosis factor-␣ (TNF-␣) in aortic endothelial cells, fibroblasts, and vascular smooth muscle cells (SMCs). 13, 11, 14 TNF-␣ is found in human atheroma and it leads to the production of oxygen-derived free radicals. 15 The secretion of TNF-␣ by macrophages is enhanced on exposure to oxidized LDL that may accelerate the formation of atherosclerotic lesions. 16 Moreover, TNF-␣ regulates cytoskeletal organization of SMCs by inducing depolymerization of actin stress fibers and dispersion of vinculin from sites of focal adhesion. 17 ␣-Tocopherol is a well-known antioxidant and, therefore, could change the activity of transcription factors and signal transduction pathways modulated by proand antioxidant conditions. 18 Moreover, ␣-tocopherol acts specifically as an inhibitor of protein kinase C (PKC) enzymatic activity 19, 20 and can also influence transcription. [21] [22] [23] [24] In SMCs, ␣-tocopherol specifically inhibits PKC-␣, which is strongly involved in the proliferative signal transduction pathway. 25 In this study, we investigated, using gene expression arrays containing 7075 genes, whether ␣-tocopherol modulates the expression of specific genes in human aortic SMCs. We have confirmed by RT-PCR and Western blots that the expression of one gene on the gene expression array, the connective tissue growth factor (CTGF) gene, was upregulated by ␣-tocopherol in cultured human vascular SMCs and in cultured human skin fibroblasts. ␣-Tocopherol promoted upregulation was independent of the known PKC inhibition by ␣-tocopherol because this effect was also observed in SMCs in which PKC was either downregulated or inhibited. We have provided evidence that the downregulation of CTGF expression promoted by TNF-␣ was reverted by ␣-tocopherol and other antioxidants, suggesting that this molecule can also modulate CTGF expression by acting as an antagonist of TNF-␣.
Materials and Methods

Materials
RRR-␣-tocopherol and RRR-␤-tocopherol were obtained from Henkel. N-acetylcysteine, probucol, and phorbol 12-myristate 13-acetate (PMA) were from Sigma. Calphostin C was from Calbiochem; Gö 6976 and okadaic acid (OA) were from LC Laboratories. PKC412 was from Novartis Pharma. TNF-␣ was from Alexis Biochemicals. pAP-1-luc and pTAL were from Clontech.
Human 
Cell Culture
Stock solutions of RRR-␣-tocopherol and RRR-␤-tocopherol, N-acetylcysteine and probucol were dissolved in ethanol and the concentration of the stock solutions confirmed spectrophotometrically. T/G cells were cultured in DMEM/10% FCS and used between passages 4 and 10. Human female skin fibroblasts (sample 1, 29 years old; sample 2, 1 year old; sample 3, 59 years old) were cultured in DMEM/10% FCS and used between passages 2 and 8. HCASMCs were cultured in medium 231 supplemented with smooth muscle growth supplement (SMGS) and used between passages 5 and 10. Treatments were done either with subconfluent (T/G) or confluent cells (HCASMCs) as indicated in the text.
Gene Array Experiments
Human SMCs (T/G, passage 5) were grown to Ϸ70% confluence in 18 Falcon 9-cm dishes in 10 mL DMEM/10% FCS. The medium was replaced with new medium 24 hours before the experiment. Nine dishes were treated with 50 mol/L ␣-tocopherol (10 L from 50 mmol/L stock of ␣-tocopherol in ethanol), and 9 control dishes were treated with 10 L ethanol, both for exactly 8 hours. Therefore, final ethanol solvent was below 0.1%. Afterward, cells were washed twice with cold PBS and total mRNA was isolated by using twice the Oligotex Midi mRNA isolation kit (Qiagen). Analysis of differential mRNA expression was done on Unigem V gene expression arrays at GenomeSystems.
RT-PCR and Cloning
Total RNA was isolated using a RNA extraction kit from Qiagen. Semiquantitative RT-PCR was performed according to the RT-PCR kit from Perkin-Elmer. RT-PCR for CTGF expression was performed with primer CTGFfor (5Ј-CCAAGGACCAAACCGTGGT-3Ј), which anneals to exon 3 and primer CTGFrev (5Ј-TACTCCACAGAATTTAGCTCG-3Ј), which anneals to exon 4/5. 12 PCR conditions were at 95°C, 30 seconds; 55°C, 30 seconds; and 72°C, 30 seconds for 22 cycles, and the expected fragment was 311 bp long. Control reactions were performed with primers GAP1 (5Ј-AGCCACATCGCTCAGACACC-3Ј) and GAP2 (5Ј-TGAGGCTGTTGTCATACTTCTC-3Ј), which are specific for the human glyceraldehyde-3-dehydrogenase (GAPDH) exons 2 and 6, respectively. PCR conditions were at 95°C, 30 seconds; 68°C, 30 seconds; and 72°C, 30 seconds for 18 cycles, and the expected fragment was 465 bp long. To ensure being in the linear range of the PCR reaction, a low number of PCR cycles were used, and all PCR reactions were performed in the presence of 0.2 Ci ␣ 32 P-ATP per tube. The amplification products were separated using a 6% polyacrylamide gel, dried, and exposed to Kodak X-Omat film. The autoradiograms were scanned with an image densitometer (BioRad). CTGF data are presented as meanϮSD and were calculated after normalization to the GAPDH data. The identity of the PCR fragments was confirmed by increasing the cycle number for amplification and automated sequencing (ABI-PRISM).
For cloning the CTGF promoter sequence, PCR was performed with human genomic DNA (Roche) and primer CTPROCfor (5Ј-AGGAATTCCTGCTGTTTGCC-3Ј) and primer CTPROBrev (5Ј-TGGAGCGCTGGCGGTGGT-3Ј), which both anneal to the CTGF promoter. 26 PCR conditions were at 95°C, 30 seconds; 62°C, 30 seconds; and 72°C, 1 minute for 30 cycles. The PCR fragment was isolated with the JETsorb gel extraction kit (Genomed) and cloned into pT7Blue-3 (Novagen), and clones containing an insert were sequenced with automated sequencing (ABI-PRISM). The CTGF fragment was cloned into the pGL3-basic (sense, pCT-sb; antisense, pCT-asb) luciferase reporter plasmids (Promega). For cloning of TGF-␤ response element (TGF-␤RE) into pTAL, the two oligonucleotides, CTGFREUP: 5Ј-CAGGAATGCTGAGTGTCAAGGGGTCAGGATCA-ATCCAGGAATGCTGAGTGTCAAGGGGTCAGGATCAATCCG-3Ј and CTGFRELO: 5Ј-CTAGCGGATTGATCCTGACCCCTTGACACT-CAGCATTCCTGGATTGATCCTGACCCCTTGACACTCAGCATTC-CTGAGCT-3Ј, containing a direct repeat of the TGF-␤ response element of the human CTGF promoter, were annealed and cloned into the SacI/NheI site of pTAL.
Western Blots
Western blot for CTGF was done according to standard methods. Briefly, SMCs were treated with ␣-tocopherol (50 mol/L) or ethanol for 24 hours. HCASMCs were allowed to grow to confluence. Protein content was measured using the Pierce BCA Protein Assay Reagent kit. Proteins (40 g per lane) were separated using a 10% SDS-PAGE and transferred onto PVDF membrane (NEN, DuPont).
Mouse anti-human CTGF antibody (Bachem, Switzerland), diluted at 1:500, was used as primary antibody to detect the presence of CTGF, and a horseradish peroxidase-labeled anti-mouse IgG antibody (Amersham-Pharmacia), diluted at 1:10 000, was used as secondary antibody. Monoclonal anti-␣-actin antibody was used as primary antibody to control the amount of loaded protein.
For the Western blot analysis of PKC downregulation, T/G cells were treated either with 1 mol/L PMA or vehicle (DMSO) for 24 hours. Proteins (20 g per lane) were separated using an 8% SDS-PAGE gel and electroblotted onto PVDF membrane. An anti-classical PKC isoforms antibody, clone MC-5 (Santa Cruz), was used, followed by a horseradish peroxidase-labeled anti-mouse IgG antibody, diluted at 1:10 000. Rabbit anti-human ␣-actin antibody (Sigma) was used as primary antibody to control the amount of loaded protein, in addition to BCA protein assay (Pierce).
Proteins were detected by chemiluminescence (ECL, Amersham), exposure to film, and analyzed using a Lumi imager (Roche). Data are presented as meanϮSD and were calculated after normalization to ␣-actin staining.
Transfection and Promoter Assays
CTGF promoter plasmids, pAP-1-luc, pTGF-␤-RE-luc, and Renilla luciferase control reporter vector (pRL-TK) were transfected into T/G cells and HCASMCs with SuperFect (Qiagen). Cells were then treated with compounds at concentrations indicated in the Figure legends. Promoter activity was measured using the Dual-Luciferase Assay Kit (Promega) with a TD-20/20 luminometer (Turner Designs). CTGF promoter-firefly-luciferase activity was normalized to
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the TK promoter-renilla-luciferase activity, and the activity of the ethanol-treated CTGF promoter was set to 100%.
Results
Identification of ␣-Tocopherol Responsive Genes With Gene Expression Arrays
Human vascular smooth muscle cells (T/G, passage 5) were grown to Ϸ70% confluence and treated with ␣-tocopherol (50 mol/L) or ethanol as control solvent (0.1%) for 8 hours, and mRNA was isolated. The Unigem V gene expression analysis was done twice with T/G cells mRNA, from two independently performed experiments. Of the 7075 genes that were analyzed, few were responsive to ␣-tocopherol, probably due to the selection of one cell line and one time point. Among them, only a few showed a change of expression that was consistent in both experiments. The increase in the expression observed of one of these genes, the prostacyclinstimulating factor, is in accordance with the known stimulatory effect of ␣-tocopherol on prostacyclin release in human endothelial cells. 27 We decided to characterize the expression of the connective tissue growth factor (CTGF) gene, which was increased 1.8-fold on the gene array ( Figure 1A) , by a more detailed analysis.
␣-Tocopherol Induces CTGF Gene Expression in T/G Cells and Skin Fibroblasts
To evaluate the effect of ␣-tocopherol on the CTGF expression and to further confirm the results obtained from the Unigem V gene expression arrays, we performed RT-PCR using specific primers for this gene. Figure 1B shows that incubation of human SMCs (T/G) with ␣-tocopherol (50 mol/L) induced the expression of CTGF, confirming the data derived from the gene expression arrays. This induction was observed after 2 and 8 hours of incubation (73% Ϯ4.7 and 60% Ϯ8, respectively, compared with the control cells) and was also noted after 24 hours of incubation (data not shown). However, when human SMCs were incubated with ␤-tocopherol, a molecule differing from ␣-tocopherol only on a methyl group but with similar radical-scavenging properties, no induction of CTGF gene expression was seen. We did not observe any alteration compared with the control cells in the ␤-tocopherol-treated samples even at shorter (2 hours) or longer (24 hours) incubation times (data not shown), suggesting that the stimulation of CTGF expression promoted by ␣-tocopherol is not related to its antioxidant properties.
Because it has been shown that fibroblasts are the major source of CTGF production, we tested for the ability of ␣-tocopherol to stimulate CTGF expression in that particular cell type. When different cell lines of human female skin fibroblasts were incubated with 50 mol/L ␣-tocopherol for 8 hours, induction of CTGF expression was observed (209Ϯ13%, sample 1; 70Ϯ1.8%, sample 2; and 270Ϯ25%, sample 3) ( Figure 1C ). Hence, ␣-tocopherol stimulation of CTGF expression can occur also with cultured human fibroblasts, thus suggesting ␣-tocopherol as a putative stimulus for extracellular matrix deposition.
␣-Tocopherol Stimulates CTGF Protein Expression in T/G cells and HCASMCs
The next step was to evaluate whether the stimulation of CTGF transcription by ␣-tocopherol was also reflected at the level of protein expression. In all cases studied, CTGF protein was very low, but sufficient to detect ␣-tocopherol-induced changes of its expression. Two different strains of SMCs, T/G and HCASMCs, which express SMC ␣-actin when confluent (data not shown), were used to further confirm the results observed at the transcriptional level. Cells were treated with 50 mol/L ␣-tocopherol for 24 hours. When ␣-tocopherol was added to the culture medium, a significant increase in CTGF protein (139.4Ϯ8.6% for T/G and 184.3Ϯ10.1% for HCASMCs) was observed (Figure 2 ), indicating that the ␣-tocopherol stimulation of CTGF mRNA expression leads to induction of CTGF protein. In the conditioned media, no CTGF was detectable under the employed experimental conditions (24 hours treatment), as it was previously described for mesangial cells and fibroblasts. 28, 29 
␣-Tocopherol Induction of CTGF Expression Is a PKC-Independent Phenomenon
Because ␣-tocopherol inhibits PKC activity in human smooth muscle cells, 30, 31 and a recent study showed the effect of PKC on CTGF gene expression, 32 we tested for the role of PKC on the ␣-tocopherol stimulation of CTGF expression. To this end, PKC was downregulated in T/G cells by prolonged exposure to PMA (1 mol/L for 24 hours). Figure 3A shows that after this treatment the classical isoforms of PKC were undetectable by Western blot analysis. After this, the PKCdownregulated human SMCs were incubated in the presence of 50 mol/L ␣-tocopherol for 8 hours, and CTGF expression was assessed by RT-PCR as described above. Under these conditions, we still observed 69Ϯ9.8% increased expression of CTGF, suggesting that the effect of ␣-tocopherol is not mediated by modulation of PKC ( Figure 3B ). In line with this, PKC downregulation did not lead to any change of CTGF protein expression in SMCs. We also incubated human SMC with several PKC inhibitors such as calphostin C (data not shown), the indolocarbazole Gö 6976 (20 nmol/L), and the staurosporine derivative PKC412 (1 mol/L), 33 and no effect on the basal level of CTGF protein expression was observed ( Figure 3C ). In summary, induction of CTGF expression appears not to be linked to the tocopherolmediated inhibition of PKC.
TNF-␣ Downregulates CTGF Gene Expression and This Effect Is Reversed by ␣-Tocopherol and Other Antioxidants
TNF-␣ is a proinflammatory cytokine with pleiotropic cellular effects, and it is expressed by SMCs in atheromatous 
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plaques. TNF-␣ has been previously described to downregulate CTGF gene expression, 13 and suppresses the TGF-␤-induced expression of CTGF. 14 In order to assess the role of ␣-tocopherol in this process, we studied the cytokine effect on CTGF mRNA levels together with the addition of different antioxidants. We compared the mRNA levels of CTGF with and without the addition of TNF-␣ (10 ng/mL) for 4 hours to the culture media. As shown in Figure 4 , TNF-␣ downregulated CTGF mRNA expression up to 58.4Ϯ15%. When ␣-tocopherol (50 mol/L) was added together with TNF-␣, the effect of the latter was completely reversed. Similar results were found with ␤-tocopherol, probucol, and N-acetylcysteine.
␣-Tocopherol Stimulates CTGF Promoter Activity
To assess the mechanism of CTGF induction by ␣-tocopherol, the promoter of the CTGF gene was cloned upstream of the luciferase reporter gene (pCT-sb). T/G cells and HCASMCs were transfected with pCT-sb and treated for 24 hours with ␣-tocopherol. Luciferase activity was enhanced up to 33% in T/G cells and 265% in HCASMCs, showing that ␣-tocopherol may act via increasing the CTGF promoter activity ( Figure 5A ). Two previously described elements present in the CTGF promoter, TGF-␤-RE and AP-1, 12 were cloned in front of a thymidine kinase promoter luciferase reporter construct. Transient transfection of these constructs in T/G cells shows that the two elements are mediating the effect of ␣-tocopherol on CTGF promoter activation ( Figure 5B) .
We previously showed that ␣-tocopherol increases the activity of the phosphatase PP 2 A 25 ; therefore, we studied the effect of an inhibitor of PP 2 A, okadaic acid (OA) (25 nmol/L), on the CTGF promoter. Promoter activity was enhanced by OA 5-fold, showing that the stimulatory effect of ␣-tocopherol on CTGF is not due to PP 2 A activation. Moreover, when ␣-tocopherol was added together with OA, the effect of CTGF activation was partially reversed ( Figure  6 ). On the other hand, TGF-␤-RE was still responsive to ␣-tocopherol despite that OA did not have an effect on this element ( Figure 6 ).
In general, we observed that the ␣-tocopherol-mediated CTGF induction was higher when PP 2 A was inhibited by OA (compare Figures 5 and 6 ). This may be explained in that ␣-tocopherol-stimulated PP 2 A activity normally counteracts the stimulatory effect of ␣-tocopherol on CTGF promoter, whereas in the presence of OA this effect does not occur. Taken together, these results show that the induction of the CTGF promoter by ␣-tocopherol may occur via the TGF-␤ response element, whereas other elements are regulated by OA.
Discussion
Several epidemiological studies have shown that ␣-tocopherol supplementation has preventive effects in atherosclerosis, 34 whereas other studies showed no effect. 35 These paradoxical results can be partially explained by the differences in the population groups (eg, gender, age, and other factors) and onset of supplementation in patients with late stages of the disease. Other studies suggest beneficial effects of ␣-tocopherol during wound repair. 36 Whether these beneficial effects are mediated by the antioxidant function of ␣-tocopherol or by the nonantioxidant modulation of signal transduction pathways and/or gene expression is not known.
Using gene expression arrays, we have identified the connective tissue growth factor (CTGF) gene, among others, as being reproducibly modulated by ␣-tocopherol in human vascular SMCs. We focused in a further characterization on the CTGF gene because other studies showed a role of this factor in wound repair and atherosclerosis. In human cultured SMCs and skin fibroblasts, CTGF expression was stronger increased by ␣-tocopherol when compared with other antioxidants. Transient expression of CTGF is involved in normal repair processes such as wound healing and permanently overexpressed in pathological events. 11, 7 Moussad et al 37 suggest that CTGF can play different roles depending on the site and timing of expression. The level of expression may also be important, because CTGF has been demonstrated to be highly overexpressed during fibrotic disease and atherosclerosis. The upregulation of CTGF by ␣-tocopherol seen in our study in cultured SMCs and fibroblasts is most likely not sufficient to generate pathological effects. Further in vivo experiments will be required to evaluate at what level of CTGF overexpression becomes causal for fibrotic diseases, and whether an upregulation of CTGF in atherosclerosis and wound repair could provide a benefit.
Searching for the mechanism of the ␣-tocopherol-mediated upregulation of CTGF expression, we found that TNF-␣, a major inflammatory cytokine found in atheromas 38 and wounds, suppresses CTGF expression at the mRNA level. These results are supported by recent reports about TNF-␣, which show suppression of levels of CTGF in bovine aortic endothelial cells and fibroblasts. 13, 14 Inhibition of CTGF mRNA expression by TNF-␣ was partially reversed by ␣-tocopherol, suggesting that ␣-tocopherol can act like an antagonist of TNF-␣-induced CTGF downregulation. However, the suppressive effect of TNF-␣ was also efficiently counteracted by ␤-tocopherol and other antioxidants, suggesting that this event is primarily mediated by oxidative stress.
At the protein level, CTGF induction was of the same orders as that of its mRNA, thus excluding the possibility that ␣-tocopherol could result in lesion formation. In pathological situations, where stronger signals lead to higher CTGF expression, ␣-tocopherol may efficiently suppress them. 39 Our results show that ␣-tocopherol does not modulate CTGF expression via inhibition of PKC, because CTGF mRNA levels were not affected when PKC was downregulated by the addition of PMA. Moreover, incubation with several PKC inhibitors did not change the basal expression of CTGF, suggesting other mechanisms of CTGF expression induction by ␣-tocopherol, possibly via the direct stimulation of an AP-1 response element or others present in the CTGF promoter. ␣-Tocopherol-mediated upregulation of CTGF may take place via modulation of the TGF-␤ signaling pathway, because we observed that the TGF-␤ response element located in the promoter is responsive to ␣-tocopherol treatment. TGF-␤ stimulates CTGF expression in human aortic SMCs by interfering with the activity of peroxisome proliferator-activated receptor-␥ (PPAR-␥) and Smad3. 40 On the other hand, TGF-␤ decreases the expression of CD36 scavenger receptor by reducing the PPAR-␥ activity, 41 and ␣-tocopherol inhibits CD36 expression possibly also by interfering with PPAR-␥. 22, 42 Taken together, it can be speculated that ␣-tocopherol may interfere with the PPAR-␥ activity, thus leading to activation of CTGF expression, or reduction of CD36 expression.
When extrapolated to the in vivo situation, ␣-tocopherol may support connective tissue cells during wound repair and vessel damage by stimulating the synthesis of CTGF and thus extracellular matrix, either by interfering with TNF-␣ or by directly acting on the CTGF promoter. Upregulation of CTGF expression by ␣-tocopherol in SMCs may increase the resistance of vascular cells to vessel injuries, thus acting as an atherosclerosis-preventing agent. Moreover, the beneficial ␣-tocopherol effects in some epidemiological studies in patients with advanced atherosclerosis may be explained by transient CTGF overexpression. In fact, plaques with a soft lipid core, and thus prone to rupture and embolism, may become covered by a fibrous connective tissue cap, separating and stabilizing the plaque material from the luminal blood flow. CTGF is overexpressed in advanced atherosclerotic lesions, and CTGF expressing cells are localized in areas with increased connective tissue accumulation, such as the shoulder of the fibrous cap. 6 Thus, ␣-tocopherol-mediated induction of CTGF expression may lead to enhanced deposition of extracellular matrix and thus stabilize the cap, possibly explaining its beneficial effect also in advanced atherosclerotic situations.
